Atopic Dermatitis Drugs Market Size & Share 2026-2035

Atopic Dermatitis Drugs Market Size

The global atopic dermatitis drugs market was valued at USD 13.2 billion in 2025 and is projected to grow from USD 14.4 billion in 2026 to USD 34.4 billion by 2035, expanding at a CAGR of 10.1%, according to the latest report published by Global Market Insights Inc.

The global market for atopic dermatitis drugs is growing rapidly, mainly due to the increasing number of cases of atopic dermatitis worldwide and the fast development of advanced drugs. Atopic dermatitis, a chronic inflammatory skin disease that is one of the most common and debilitating conditions, is still showing a rising trend in both children and adults. According to the International Eczema Council, as of 2022, it affects almost 20% of children and 10% of adults worldwide, making it a significant clinical and social issue. This steady rise in the number of cases of the disease reiterates the need for effective and long-term pharmacological treatment.

The market is also seeing significant investment in research and development as the pharmaceutical companies are trying to develop new products. The major players in the industry are expected to benefit in the coming years due to the rising number of favourable outcomes from late-stage clinical trial drugs. For example, in April 2021, Galderma Laboratories announced positive phase 2b results for their uncontrolled atopic dermatitis drug nemolizumab. In March 2021, Pfizer also confirmed that their drug in development, abrocitinib, was not inferior to Sanofi’s established drug Dupixent.

Additionally, there is an unmet need for oral medications in this disease which can be met by abrocitinib, a JAK1 inhibitor, in the atopic dermatitis patient population that requires treatment with oral medications. These advancing drug pipelines, alongside expected new oral medications, are expected to boost the expansion of the atopic dermatitis market. The top 5 players in this market are Sanofi, AbbVie, Pfizer, Eli Lilly and Company and LEO Pharma.

Furthermore, the rapid advancement of topical therapies most notably the introduction of ruxolitinib cream as a targeted JAK‑inhibiting option is reshaping the management of mild‑to‑moderate atopic dermatitis, particularly in pediatric and adolescent populations who require safe alternatives. As these innovations gain broader clinical adoption and real‑world outcomes continue to validate their long‑term benefits, they translate into expanding therapeutic utilization, reinforcing a multi‑route and multi‑class treatment framework that is expected to drive steady growth within the market.

Atopic dermatitis drugs are pharmaceutical treatments to treat atopic dermatitis (AD) and its associated skin symptoms, including inflammation, itching, and skin dryness. These drugs focus on curing flare-ups, inflammation and controlling skin condition. These drugs include topical treatments, systemic treatments, and biological medicines that vary according to the severity of the condition.

Atopic Dermatitis Drugs Market Trends

• Recent advancements in atopic dermatitis therapeutics have significantly strengthened the precision, durability, and overall effectiveness of disease management, driven by the expanding availability of biologics, targeted small‑molecule agents, and age‑specific treatment approvals.
   
• These innovations enhance clinicians’ ability to address underlying type‑2 inflammatory pathways, improving symptom resolution, long‑term disease control, and patient quality of life across diverse age groups. The addition of infant and pediatric indications, in particular, has broadened the therapeutic landscape, enabling earlier intervention in high‑burden cases.
   
• A major breakthrough is the expanding use of biologic therapies tailored to pediatric patients, offering targeted immune modulation with high specificity and favorable safety profiles.
   
• A key example is the FDA’s approval of Dupixent (dupilumab) in June 2022 for children six months to five years old, making it the first biologic agent approved from infancy through adulthood for moderate‑to‑severe atopic dermatitis. This approval allows clinicians to deliver earlier, more precise disease control in a population historically limited to topical corticosteroids.
   
• These expanding approvals and next‑generation therapies are fundamentally transforming the atopic dermatitis treatment paradigm. As clinical adoption increases and long‑term real‑world evidence accumulates, these therapies are expected to drive substantial market growth by improving patient outcomes, expanding treatable populations, and elevating standards of care across both pediatric and adult segments.
   

Atopic Dermatitis Drugs Market Analysis

Based on drug class, the market is segmented into corticosteroids, calcineurin inhibitors, biologics, phosphodiesterase-4 (PDE-4) inhibitors, and other drug classes. The biologics segment dominated the market with the market share of 41.4% in 2025.
 

• Biologic therapies are playing a central role in the management of moderate‑to‑severe atopic dermatitis, offering highly targeted intervention against key inflammatory pathways. By selectively modulating cytokines such as IL‑4, and IL‑31, biologics provide deeper, more durable symptom control compared with conventional topicals and systemic immunosuppressants, thereby significantly improving skin clearance, reducing flare frequency, and enhancing patient quality of life.
   
• High‑precision immune targeting and pathway‑specific mechanisms have strengthened biologics’ ability to address chronic, relapsing disease patterns. These agents minimize broad immunosuppression and instead act on defined molecular drivers of inflammation, enabling sustained disease management with favorable long‑term safety profiles.
   
• Moreover, advancements in next‑generation biologics continue to accelerate clinical adoption, driven by expanding indications, strong efficacy signals, and robust late‑stage pipelines. These ongoing trials include evaluations of real‑world effectiveness and long‑term outcomes in adolescents and adults, as well as pediatric studies, underscoring its rising importance within the future biologic landscape.
   
• Further, the biologics segment is supported by continuous innovation in clinical development, including long‑term extension studies, disease‑specific efficacy assessments, and expanded evaluation across diverse demographic groups. As more biologics achieve regulatory approval and demonstrate durable response rates particularly in patients inadequately controlled by topicals or small‑molecule therapies the segment is expected to maintain strong momentum and drive significant overall market growth.
   

Based on route of administration, the atopic dermatitis drugs market is segmented into injectable, topical, and oral. The injectable segment dominated the market with the largest revenue share of 45.2% in 2025.
 

• The expansion of injectable options for atopic dermatitis is attributed to the development of new biologic drugs that target distinct inflammatory pathways including IL-4, IL-13, and JAK inhibitors. This diversification of therapeutic options is a major factor of growth in the injectable segment.
   
• Similarly, the U.S FDA and EMA have authorized the use of several injectable biologics for the treatment of atopic dermatitis, which has expedited their market entry and availability. The rapid approval of these drugs in large markets is increasing their adoption rates.
   
• For instance, in September 2024, Eli Lilly and Company reported that their EBGLYSS (lebrikizumab-lbkz) 250 mg/2ml injection was approved by the U.S. FDA, which is a targeted IL-13 inhibitor for the treatment of patients aged twelve years and older.
   

Based on patient demographics, the atopic dermatitis drugs market is bifurcated into pediatric and adults. The pediatric segment dominated the market with the largest revenue of USD 9.5 billion in 2025.
 

• The increasing incidence of atopic dermatitis, particularly amongst children, remains an important driver for the pediatric treatment market. For instance, the National Eczema Association suggests that roughly 1 in 10 people will get AD with the greatest incidence during their early childhood years. Such a high incidence is generating a stronger need for appropriate treatment options designed for children which is in turn, growing the market for pediatric atopic dermatitis therapeutics.
   
• Additionally, the new market opportunities are also fueled by the approval of new treatment therapies for pediatric use. For instance, in May 2020, the Food and Drug Administration (FDA) gave marketing authorization to Dupixent for the treatment of children aged 6 to 11 years with moderate-to-severe atopic dermatitis, which is a remarkable advancement in pediatric dermatology.
   
• In addition, the expansion of the market is being aided by the FDA's accelerated approval of pediatric formulations of biologic therapy drugs. This would lead to increased market growth along with innovative products and services being available more rapidly, which would benefit children suffering from atopic dermatitis.

Based on distribution channel, the atopic dermatitis drugs market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment dominated the market with the largest revenue of USD 6.4 billion 2025.
 

• Hospital pharmacies play a central role in delivering and managing therapeutic care for patients with severe atopic dermatitis who require inpatient support, particularly in cases where treatment intensity, disease complications, or comorbid conditions necessitate hospitalization. These settings ensure consistent access to specialized medications that may not be readily available in retail pharmacy channels, including advanced systemic agents and tightly controlled therapies.
   
• In addition, hospital pharmacy services are integral to the safe administration and monitoring of systemic biologic treatments and advanced immunomodulators, many of which require close observation due to their potential for clinically significant side effects.
   
• Within the hospital environment, pharmacists and clinicians can conduct structured monitoring, manage infusion‑ or injection‑related events, adjust dosing regimens, and track therapeutic outcomes with greater precision.
   
• Further, hospital‑based dispensing and monitoring pathways contribute to continuity of care for patients transitioning between inpatient, outpatient, and specialty‑care settings, particularly those initiating biologics or undergoing therapy adjustments. By integrating pharmacy oversight with dermatology, immunology, and nursing teams, hospital pharmacies strengthen treatment safety, improve clinical outcomes, and support broader adoption of advanced atopic dermatitis therapies across the healthcare system.
   

North America Atopic Dermatitis Drugs Market

• North America accounted for the largest share of the global market in 2025, supported by its advanced dermatology care infrastructure, high treatment accessibility, and the rapid adoption of biologics and targeted immunomodulators.
   
• The region benefits from well‑established regulatory systems such as the U.S. FDA and Health Canada, which facilitate timely approval of high‑quality therapies and ensure consistent clinical standards for AD management.
   
• A key driver of North America’s dominance is the substantial disease burden of atopic dermatitis across the region. According to NIH (2021), the one‑year adult prevalence of AD reached 4.9% in the U.S., 3.5% in Canada, underscoring a sizeable and expanding patient population that requires long‑term disease management.
   
• This high prevalence amplifies demand for advanced therapy classes including biologics, JAK inhibitors, and non‑steroidal topicals particularly for moderate‑to‑severe cases unresponsive to first‑line treatments.
   
• With continuous innovation, strong clinical guidelines, and expanding use of digital dermatology tools and remote‑care models, North America is expected to maintain its leading market position over the forecast period.
   

The U.S. atopic dermatitis drugs market was valued at USD 4.3 billion and USD 4.7 billion in 2022 and 2023, respectively. The market size reached USD 5.5 billion in 2025, growing from USD 5.1 billion in 2024.
 

• Growing emphasis of regional and national agencies such as the National Eczema Association (NEA), towards increasing awareness regarding atopic dermatitis and available treatment options, along with advocating for more appropriate research, funding, as well as better access to medications, are key factors driving the demand for these drugs in the country.
   
• The NEA, for instance, announced in March 2022 the opening of its 2022 research grant cycle for awards of eczema related research totaling USD 760,000. The efforts of these organizations mobilize public and healthcare industry attention towards new and effective treatments and therapies which can improve outcomes and quality of life for millions of people around the globe.
   
• In addition, the grant was awarded by the U.S. Food and Drug Administration (FDA) for speed approval on the number of biologic medications for atopic dermatitis, especially strongly expressed in children and severe patients.
   
• For instance, the FDA in February 2021 gave Fast-Track designation to Asana BioSciences' oral dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), - gusacitinib (ASN002), intended for treatment of moderate-to-severe Chronic Hand Eczema (CHE). The support from regulatory authorities has led to a quicker market introduction of new medicines that are greatly needed in the rapidly evolving atopic dermatitis market.
   

Europe Atopic Dermatitis Drugs Market

The Europe market accounted for USD 2.7 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Europe held a strong and well‑established position in the global market in 2025, supported by its advanced dermatology infrastructure, widespread specialist care availability, and a mature network of hospitals and dermatology centers across EU member states. With a one‑year adult AD prevalence of 4.4% in the region, as reported by NIH in 2021, the population‑level disease burden creates sustained clinical demand for effective long‑term therapies.
   
• The region’s strong focus on early diagnosis, structured disease management, and standardized dermatological pathways enables broad adoption of advanced AD therapies, including biologics, oral immunomodulators, and non‑steroidal topical agents.
   
• High awareness among clinicians and patients, coupled with widespread access to specialist care, drives consistent utilization of evidence‑based treatment algorithms for mild, moderate, and severe AD.
   
• With ongoing innovation in immunodermatology, increasing penetration of biologics, and expanding access to digital dermatology solutions, Europe is expected to maintain a strong and growing presence in the global market over the forecast period.
   
• The region’s emphasis on early intervention, chronic disease management, and equitable access to advanced therapies ensures sustained demand and solidifies its long‑term leadership in the AD treatment landscape.
   

The atopic dermatitis drug market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The increase in allergies and environmental factors such as pollution in the UK is resulting in a higher incidence of atopic dermatitis. For instance, the Department for Environment, Food & Rural Affairs (DEFRA) highlighted that air pollution in many cities is above the recommendations of the World Health Organization (WHO). This points towards the need for further therapies that not only improve the symptoms of atopic dermatitis but also tackle its root cause.
   
• In addition, the healthcare systems in the UK allow reimbursement for effective and expensive biologics and JAK inhibitors making it easier for patients to access therapy. For instance, Leo Pharma’s Adtralza, which is a biologic drug, and the IL-13 blocker were reimbursed by National Institute for Health and Care Excellence (NICE) in June 2022.
   

Asia Pacific Atopic Dermatitis Drugs Market

The Asia Pacific region is projected to show a lucrative growth of about 10.4% during the forecast period.
 

• Asia‑Pacific is rapidly emerging as one of the fastest‑growing regions in the global market, driven by its large and diverse population, expanding access to dermatology care, and increased awareness of chronic inflammatory skin diseases. The region spans heterogeneous healthcare systems ranging from high‑income economies such as Japan, South Korea, and Singapore to rapidly developing markets creating significant opportunities for market expansion.
   
• The overall disease burden of atopic dermatitis in Asia Pacific remains substantial, with 68.1 million cases recorded in 2021, representing a 16.1% increase since 1990. Notably, the highest disability‑adjusted life years (DALYs) rates were observed in high‑income Asia Pacific and Central Asia, underscoring the region’s significant unmet clinical need and the quality‑of‑life impact of AD.
   
• This expanding clinical burden is accelerating demand for advanced AD therapies, including biologics, targeted small‑molecule drugs (JAK inhibitors), and non‑steroidal topical agents. As patients and clinicians increasingly shift away from long‑term corticosteroid reliance, the adoption of evidence‑based treatment guidelines and modern therapeutic classes is rising across Japan, South Korea, Australia, China, and emerging Southeast Asian markets.
   
• With a large population base, growing healthcare accessibility, and rising adoption of advanced immunodermatology therapies, Asia Pacific is expected to remain one of the fastest‑growing regions in the global market. The region’s increasing focus on early diagnosis, digital healthcare integration, and long‑term disease management will continue to support robust growth throughout the forecast period.
   

Japan market is anticipated to witness lucrative growth between 2026 – 2035.

• Japan is a key market in the Asia‑Pacific region for atopic dermatitis treatments, supported by its highly advanced healthcare infrastructure, strong clinical standards, and widespread access to dermatology specialists across major hospitals and urban medical centers. The country’s well‑developed healthcare delivery system enables timely diagnosis, structured treatment pathways, and adoption of innovative therapies for chronic inflammatory skin diseases.
   
• Atopic dermatitis represents a significant and growing clinical burden in Japan, particularly among children and young adults. According to NIH data, the prevalence of AD among children in mainland Japan is notably high at 12–13%, underscoring the need for effective long‑term management strategies.
   
• This elevated prevalence is closely linked to urban living environments, lifestyle changes, and shifts toward westernized diets, which have contributed to rising rates of inflammatory and allergic skin conditions.
   
• Environmental and lifestyle transformations such as increased urbanization, pollution exposure, and dietary westernization continue to intensify AD severity and case volume, increasing reliance on advanced therapeutic options. As these factors elevate allergic and inflammatory tendencies in the population, demand grows for treatments that provide durable control, reduce symptom recurrence, and improve overall quality of life.
   

Latin America Atopic Dermatitis Drugs Market

Brazil is experiencing significant growth in the market.
 

• Brazil represents one of the most important and steadily expanding markets for atopic dermatitis therapies in Latin America, driven by its large population, broad epidemiological burden, and increasing prioritization of dermatological care within the public and private healthcare systems.
   
• With approximately 2.7% of individuals affected by AD nationally, the disease constitutes a significant public health concern requiring long‑term management and sustained therapeutic access.
   
• The country faces a substantial and diverse clinical burden of AD, with an estimated 1.5 million adults and 438,000 elderly individuals living with the condition. This high prevalence across age groups highlights the need for timely diagnosis, adequate treatment pathways, and broader access to advanced pharmacologic options, including non‑steroidal topicals, immunomodulators, JAK inhibitors, and biologics for moderate‑to‑severe cases.
   
• Brazil’s rising number of AD‑related hospitalizations further underscores the seriousness of the disease, particularly in individuals with unstable, severe, or poorly controlled symptoms.
   
• In 2023, the country recorded 411 hospitalizations among adults and 264 hospitalizations among elderly patients, indicating substantial healthcare utilization driven by exacerbations, infections, or complications associated with chronic inflammatory skin disease.
   
• With growing investment in dermatology infrastructure, improving access to specialty care, and rising adoption of innovative AD treatments, Brazil is positioned to remain a key growth market for atopic dermatitis therapies in Latin America.
   

Middle East and Africa Atopic Dermatitis Drugs Market

The market in Saudi Arabia is expected to experience significant and promising growth from 2026 to 2035.
 

• Saudi Arabia’s climatic conditions play a significant role in exacerbating atopic dermatitis, as the country’s hot, dry desert environment contributes to persistent skin dryness, barrier disruption, and increased likelihood of flare‑ups. Seasonal factors such as low humidity, extreme heat, and frequent sand exposure intensify irritation and heighten sensitivity among AD patients, driving greater need for effective, long‑term treatment solutions.
   
• Environmental stressors including high pollution levels and recurrent sandstorms further aggravate AD symptoms, increasing inflammation, pruritus, and overall disease severity.
• According to the Saudi Ministry of Health, air pollution in major cities frequently exceeds WHO guidelines, with average PM2.5 levels reaching approximately 81 µg/m³ in 2023, far above the recommended annual limit of 5 µg/m³. Such elevated particulate matter concentrations are closely linked to worsening allergic and inflammatory skin diseases, reinforcing the urgent need for comprehensive AD management strategies.
   
• These environmental and climatic pressures collectively accelerate demand for advanced dermatology care and modern atopic dermatitis therapies in Saudi Arabia.
   

Atopic Dermatitis Drugs Market Share

• The market is highly competitive, characterized by a mix of established global pharmaceutical leaders and innovative emerging companies developing advanced immunodermatology solutions. Market players are strengthening their competitive positions through biologic innovation, development of targeted small‑molecule therapies, expansion of topical non‑steroidal options, and increasing use of collaborative research partnerships with dermatology networks, academic institutions, and clinical research centers.
   
• Leading companies such as Sanofi, AbbVie, Pfizer, Eli Lilly and Company and LEO Pharma collectively account for approximately 45% of the global market. These firms benefit from extensive portfolios spanning biologics and advanced topical therapies aimed at reducing flareups, improving skin barrier function, and offering sustained symptom control.
   
• Overall, the competitive dynamics of the market continue to be shaped by rapid therapeutic innovation, growing adoption of targeted immunotherapies, regulatory support enabling streamlined approvals, and the rising global disease burden. These factors collectively ensure strong market momentum, sustained demand, and steady growth throughout the forecast period.
   

Atopic Dermatitis Drugs Market Companies

Some of the eminent market participants operating in the atopic dermatitis drugs industry include:

• AbbVie
• Arcutis Biotherapeutics
• Chugai Pharmaceutical
• Eli Lilly and Company
• Galderma Laboratories
• Incyte Corporation
• Leo Pharma
• Maruho
• Otsuka Pharmaceutical
• Pfizer
• Sanofi
• Viatris
   
• AbbVie

AbbVie is a leading global innovator in immunodermatology, advancing the treatment landscape for moderate‑to‑severe atopic dermatitis through highly targeted, next‑generation therapeutics. The company’s flagship oral JAK1 inhibitor, RINVOQ (upadacitinib), has rapidly become one of the most significant systemic treatment options for AD, addressing unmet needs among patients whose disease is inadequately controlled by topical agents or biologics.
 

• Sanofi

Sanofi is a leading global force in immunology and dermatology, driven by the exceptional market performance, clinical impact, and broad indication expansion of its flagship biologic, Dupixent (dupilumab). Through sustained innovation and strong clinical evidence across multiple type‑2 inflammatory diseases including atopic dermatitis Sanofi continues to reshape therapeutic standards worldwide.
 

• Pfizer

Pfizer is a major innovator in the atopic dermatitis market, advancing targeted oral immunomodulation through its JAK1 inhibitor, CIBINQO (abrocitinib). CIBINQO offers a once‑daily oral option for moderate‑to‑severe AD patients whose disease remains uncontrolled with other systemic therapies, including biologics.
 

Atopic Dermatitis Drugs Industry News
 

• In May 2024, Johnson & Johnson announced the acquisition of Proteologix, a private biotechnology firm specializing in bispecific antibodies for immune-mediated diseases. Through this acquisition, J&J acquired Proteologix’s portfolio, including PX128, a bispecific antibody targeting IL-13 and TSLP, set to enter phase 1 trials for moderate-to-severe atopic dermatitis and asthma, and PX130, targeting IL-13 and IL-22, in preclinical development for moderate-to-severe atopic dermatitis. The acquisition also provided J&J with additional bispecific antibody programs, enhancing its capacity to develop innovative treatments across various diseases.
   
• In January 2024, Pfizer and Glenmark Pharma collaborated to launch abrocitinib, an advanced oral systemic treatment for moderate-to-severe atopic dermatitis, in India. Developed by Pfizer, abrocitinib received marketing authorization from India’s Central Drugs Standard Control Organization and approval from the US FDA, EMA, and other regulatory bodies, according to a company statement. This launch strengthened both companies' presence in the dermatology market.
   

The atopic dermatitis drugs market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Corticosteroids
• Calcineurin inhibitors
• Biologics
• Phosphodiesterase-4 (PDE-4) inhibitors
• Other drug classes

Market, By Route of Administration

• Topical
• Oral
• Injectable

Market, By Patient Demographics

• Pediatric
• Adults

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce
   

The above information is provided for the following regions and countries:

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Spain
• Italy
• Netherlands

• Asia Pacific

• China
• Japan
• India
• Australia
• South Korea

• Latin America

• Brazil
• Mexico
• Argentina

• Middle East and Africa

• South Africa
• Saudi Arabia
• UAE